CN109195987B - 针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用 - Google Patents

针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用 Download PDF

Info

Publication number
CN109195987B
CN109195987B CN201780014099.2A CN201780014099A CN109195987B CN 109195987 B CN109195987 B CN 109195987B CN 201780014099 A CN201780014099 A CN 201780014099A CN 109195987 B CN109195987 B CN 109195987B
Authority
CN
China
Prior art keywords
ser
val
leu
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780014099.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109195987A (zh
Inventor
N·普瓦里耶
C·马里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSE Immunotherapeutics SA
Original Assignee
OSE Immunotherapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSE Immunotherapeutics SA filed Critical OSE Immunotherapeutics SA
Publication of CN109195987A publication Critical patent/CN109195987A/zh
Application granted granted Critical
Publication of CN109195987B publication Critical patent/CN109195987B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780014099.2A 2016-02-29 2017-02-28 针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用 Active CN109195987B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301271P 2016-02-29 2016-02-29
US62/301,271 2016-02-29
PCT/IB2017/000293 WO2017149394A1 (en) 2016-02-29 2017-02-28 Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment

Publications (2)

Publication Number Publication Date
CN109195987A CN109195987A (zh) 2019-01-11
CN109195987B true CN109195987B (zh) 2022-05-27

Family

ID=58530580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780014099.2A Active CN109195987B (zh) 2016-02-29 2017-02-28 针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用

Country Status (23)

Country Link
US (1) US11230602B2 (enExample)
EP (1) EP3423496B1 (enExample)
JP (1) JP7053479B2 (enExample)
KR (1) KR102819051B1 (enExample)
CN (1) CN109195987B (enExample)
AU (1) AU2017225495B2 (enExample)
BR (1) BR112018067479A2 (enExample)
CY (1) CY1122072T1 (enExample)
DK (1) DK3423496T3 (enExample)
ES (1) ES2737307T3 (enExample)
HR (1) HRP20191445T1 (enExample)
HU (1) HUE045183T2 (enExample)
IL (1) IL261330B2 (enExample)
LT (1) LT3423496T (enExample)
MA (1) MA43767B1 (enExample)
MD (1) MD3423496T2 (enExample)
ME (1) ME03446B (enExample)
PL (1) PL3423496T3 (enExample)
PT (1) PT3423496T (enExample)
RS (1) RS59223B1 (enExample)
SI (1) SI3423496T1 (enExample)
SM (1) SMT201900460T1 (enExample)
WO (1) WO2017149394A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2019043065A1 (en) * 2017-08-29 2019-03-07 Ose Immunotherapeutics METHOD AND PREPARATION FOR SORTING T EFFECTOR LYMPHOCYTES USING ANTI-CD127 ANTIBODIES FOR CELL THERAPY APPLICATIONS
EP3790898A4 (en) * 2018-05-10 2022-03-02 Neuracle Science Co., Ltd SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF
JP2022539753A (ja) * 2019-06-28 2022-09-13 ザ ユニバーシテイ オブ メルボルン ガンマデルタｔ細胞を阻害する、または活性化させる方法
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
CA3181394A1 (en) * 2020-04-27 2021-11-04 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting cd127 and use thereof
WO2021236691A1 (en) * 2020-05-18 2021-11-25 Jumaa Weinacht Hassan Composition for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038254A (zh) * 2010-02-24 2013-04-10 瑞纳神经科学公司 拮抗性抗il-7受体抗体及方法
WO2015189302A1 (en) * 2014-06-10 2015-12-17 Effimune Antibodies directed against cd127

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2655392A1 (en) 2006-05-31 2007-12-06 The Regents Of The University Of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
PE20121702A1 (es) 2010-01-28 2012-12-14 Glaxo Group Ltd Proteinas de enlace cd127
EP2583980A1 (en) * 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
US20150297310A1 (en) 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038254A (zh) * 2010-02-24 2013-04-10 瑞纳神经科学公司 拮抗性抗il-7受体抗体及方法
WO2015189302A1 (en) * 2014-06-10 2015-12-17 Effimune Antibodies directed against cd127

Also Published As

Publication number Publication date
HRP20191445T1 (hr) 2019-11-15
MA43767A (fr) 2019-01-09
AU2017225495B2 (en) 2024-05-09
IL261330B2 (en) 2023-03-01
PL3423496T3 (pl) 2020-01-31
AU2017225495A1 (en) 2018-08-23
RS59223B1 (sr) 2019-10-31
KR20180118746A (ko) 2018-10-31
DK3423496T3 (da) 2019-08-19
EP3423496A1 (en) 2019-01-09
US20200308288A1 (en) 2020-10-01
ES2737307T3 (es) 2020-01-13
EP3423496B1 (en) 2019-07-03
US11230602B2 (en) 2022-01-25
ME03446B (me) 2020-01-20
CA3014313A1 (en) 2017-09-08
MA43767B1 (fr) 2019-08-30
IL261330A (en) 2018-10-31
IL261330B (en) 2022-11-01
LT3423496T (lt) 2019-09-25
HUE045183T2 (hu) 2019-12-30
SI3423496T1 (sl) 2019-10-30
JP7053479B2 (ja) 2022-04-12
JP2019515648A (ja) 2019-06-13
SMT201900460T1 (it) 2019-09-09
PT3423496T (pt) 2019-09-05
WO2017149394A1 (en) 2017-09-08
CY1122072T1 (el) 2020-11-25
CN109195987A (zh) 2019-01-11
KR102819051B1 (ko) 2025-06-12
MD3423496T2 (ro) 2020-01-31
BR112018067479A2 (pt) 2019-01-15

Similar Documents

Publication Publication Date Title
CN109195987B (zh) 针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用
AU2022201144B2 (en) Antigen binding molecules comprising a TNF family ligand trimer
CN107207604B (zh) 抗alk2抗体
CN112175081B (zh) 抗cd137分子及其用途
RU2753902C2 (ru) Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
DK2328616T3 (en) Compositions and Methods for Antibodies to Complement Protein C5
KR102724790B1 (ko) 항 cd147 항체
AU2017250807A1 (en) Anti-PACAP antibodies and uses thereof
AU2017230091B2 (en) Activin type 2 receptor binding proteins and uses thereof
KR20180089510A (ko) CD32b를 표적화하는 항체 및 그의 사용 방법
CN108530535A (zh) 结合肽聚糖识别蛋白1的抗体
AU2020316495A1 (en) Humanized anti-VEGF Fab antibody fragment and use thereof
AU2020316498A1 (en) Humanized anti-VEGF monoclonal antibody
KR20240017054A (ko) 항-icos 항체를 사용한 pd-l1 음성 또는 저발현 암의 치료
KR20220151522A (ko) Tie2 작용제 항체 및 이의 용도
KR102920217B1 (ko) 인간화 항-vegf 단클론 항체
RU2802960C2 (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ
KR102920224B1 (ko) 인간화 항-VEGF Fab 항체 단편 및 이의 용도
RU2785293C2 (ru) Антитело против cd147
HK40109194A (zh) 抗体
CN101516913A (zh) Adcc活性得到增强的抗体及其制造方法
HK40061781A (en) Antigen binding molecules comprising a tnf family ligand trimer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant